Golden Biotechnology Corporation

As of December 31, 2024, Golden Biotechnology Corporation has 166.35M shares outstanding.

These figures are as of December 31, 2024. The price-to-sales ratio is 58.69, and the price-to-book ratio stands at 9.61.

These figures are as of December 31, 2024. The EV/Sales ratio of 62.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of December 31, 2024, Golden Biotechnology Corporation maintains a current ratio of 0.92, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 120.22, indicating elevated leverage, while an interest coverage ratio of -42.47 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2024, Golden Biotechnology Corporation posted a negative return on equity (ROE) of -109.29, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -50.22, reflecting losses generated across the asset base. Inventory turnover of 0.72 indicates how many times Golden Biotechnology Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on April 9, 2026, Golden Biotechnology Corporation's stock has declined approximately 70.34% over the past 52 weeks. The 50-day moving average sits at 13.23, while the 200-day moving average is 14.47.

Over the twelve months ended December 31, 2024, Golden Biotechnology Corporation posted a gross margin of -17.14, reflecting its pricing power and cost economics. The operating margin of -874.18 and net profit margin of -881.51 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2024. Total shareholder yield is negative at -12.15, meaning Golden Biotechnology Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Golden Biotechnology Corporation's most recent stock split took place on November 29, 2021 with a 1000:1023 split ratio.

As of December 31, 2024, Golden Biotechnology Corporation has an Altman Z-Score of -1.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.